Introduction
Over the past decades, different genome manipulation technologies have been developed to investigate the function of specific genes in vivo. Among these, the Cre/lox system has been of particular interest 1, 2 since it offers the possibility to generate tissue-specific and time-dependent knock-in (KI) or knock-out (KO) mice. To generate cardiomyocyte-specific KO mice, the α-myosin-heavy chain promoter, abbreviated MHC or Myh6 or αMyHC, has been largely used to control Cre recombinase expression (MHC-Cre + ). To date, several mouse MHC-Cre + strains have been generated in different genetic background. However, constitutive Cre expression in cardiomyocytes has been reported to alter cardiac functions 3 . Recently, Pugach et al. showed that Cre expression in MHC-Cre + heart leads to a decrease of ejection fraction in an age-dependent manner and found that wild-type genome contains loxP like sites sensitive to the Cre activity 3 . Interestingly one of these loxP like site in localized in the Dmd gene coding for the structural protein dystrophin. Dystrophin, a 427-kilodalton protein, is a key element to maintain the integrity of the lateral membrane of cardiac myocytes 4 . The absence of dystrophin, described in dystrophinopathies, leads to alter the function of calcium and sodium voltage-gated ion channels Ca v 1.2 Dystrophin and calcium current are decreased in cardiomyocytes expressing Cre enzyme driven by αMHC but not TNT promoter and Na v 1.5 and consequently triggers cardiac dysfunctions [5] [6] [7] [8] . Based on these observations, we compared the dystrophin protein expression in hearts between MHC-Cre -mice, MHC-Cre + mice, and mice deriving from the breeding of with foxed Dmd gene mouse line and MHC-Cre + mice. Unexpectedly, a reduction of dystrophin protein expression was observed in MHC-Cre + hearts compare to MHC-Cre -mice. In summary, we report on the progressive loss-of-dystrophin in one of the most used cardiac-specific Cre mouse lines, and discuss the functional consequences, in particular on cardiac ion channels.
Methods

Animals
All experiments involving animals were performed according to the Swiss Federal Animal Protection Law and have been approved by the Cantonal Veterinary Administration, Bern. This investigation conforms to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). Male mice, from three different transgenic mouse lines were used in this study. Firstly, the B6.FVB-Tg(Myh6-cre) 2182Mds/J, also known as MHC-Cre, in which the cardiac-specific α-myosin-heavy chain (Myh6) promoter drives expression of Cre was purchased from The Jackson Laboratory (Stock No 011038). Secondly, the STOCK Tg (Tnnt2-cre) 5Blh/JiaoJ also called cTnT-Cre where Cre recombinase expression is under the control of the rat cardiac troponin T2 promoter was purchased from the Jackson Laboratory (Stock No 024240). From a mixed background, these mice were bred to C57BL/6J for at least one generation upon arrival at the Jackson Laboratory. Thirdly, the Dmd flox mice in which exon 22 is flanked by loxP sites was generated by PolyGene AG (Rümlang, Switzerland).
Protein extraction and western blots
Whole hearts were extracted from mice, the atria were removed and the ventricles were homogenized in 1 ml lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 1.5 mM MgCl2, and Complete ® protease inhibitor cocktail (Roche, Basel, Switzerland) using a Polytron. Triton X-100 in lysis buffer was then added to make a final concentration of 1% (final lysate volume 2 ml). Samples were lysed on a rotating wheel for 1 hour at 4 o C. Soluble fractions of the mouse heart were obtained by subsequent centrifugation at 13 
Immunohistochemistry of mouse ventricular sections
Following removal of atria, hearts were cut transversally, embedded in Tissue-Tek ® O.C.T™ Compound (Sakura Finetek, Zoeterwoude, the Netherlands), and cryo-preserved. Frozen sections, 10μm-thick, were stored at -80 o C until later use. Sections were then thawed at room temperature for 30 minutes and subsequently fixed in cold acetone for 10 minutes. Samples were dried at room temperature for 10 minutes. After rinsing in 1X PBS, sections were blocked in 1X PBS with 0.5% Triton, 1% BSA, and 10% goat serum for 30 minutes. Sections were rinsed again in 1X PBS before addition of primary antibodies (in 1X PBS with 0.5% Triton, 1% BSA, and 3% goat serum). After 2 hours of incubation, sections were rinsed again in 1X PBS and then incubated for 1 hour in secondary antibody. After a final wash with 1X PBS, FluorSave™ Reagent (Calbiochem, La Jolla, CA, USA) was applied to the sections, which were then stored at 4 o C and analysis using confocal microscope (Zeiss Z-710).
Antibodies
For western blots, a mouse monoclonal against dystrophin (Dys NCL-DYS2, Novocastra, Muttenz, Switzerland) was used at the dilution of 1/250. A custom-made rabbit polyclonal antibody against syntrophin (Pineda Antibody. Service, Berlin) was used at a dilution of 1/1000. A mouse monoclonal antibody against SAP97 (VAM-PS005F, Enzo life science, Lausen, Switzerland) was used at a dilution of 1/500. Against Na v 1.5, a custom rabbit polyclonal antibody (Pineda Antibody. Service, Berlin) was used at a dilution of 1/200. A rabbit polyclonal antibody against Cre (69050; Novagen, EMD Millipore-MERK, Schaffhausen, Switzerland) was used at a dilution of 1/500 and rabbit polyclonal antibody against calnexin (C4731; Sigma-Aldrich, Saint-Louis Missouri, USA) was used at 1/1000. For immunostainings rabbit polyclonal antibody against Cre (69050; Novagen, EMD Millipore-MERK, Schaffhausen, Switzerland) was used at a dilution of 1/500 and mouse monoclonal anti-dystrophin (Dys NCL-DYS2, Novocastra, Muttenz, Switzerland) was used at a dilution of 1/250.
RNA extraction and quantitative RT-PCR
Total RNA was isolated from mouse heart pieces, with the ExpressArt RNAready kit (Amp Tec GmbH, Germany, provided by the lab of Pr. R. Jaggi, Bern, Switzerland). The High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies, Switzerland) was used to synthesize cDNA. Subsequently, 25 ng of cDNA was mixed with 1X TaqMan Universal Master Mix (Invitrogen) and 1 µL of either dystrophin (Dmd) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe/primer mix (Applied Biosystems; Mm00464475_m1 and Mm99999915_g1, respectively). GAPDH was used as the reference gene to which experimental data was normalized. All samples were loaded in quadruplicates. On an ABI 7500 RT-PCR machine, samples were run with the following thermal cycling conditions: holding stage at 95°C for 20 seconds, then 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Relative Dmd expression (ΔCT) was calculated by subtracting the signal threshold cycle (CT) of the control (GAPDH) from the CT value of Dmd. Subsequently, ΔΔCT values were obtained for MHCCre mice by subtracting the ΔCT of the control mice from the ΔCT of MHC-Cre mice. Results were then linearized by calculating 2 -expΔΔCT .
Isolation of mouse ventricular myocytes
Single cardiomyocytes were isolated according to a modified procedure of established enzymatic methods. Briefly, mice were euthanized by cervical dislocation. Hearts were rapidly excised, cannulated and mounted on a Langendorff column for retrograde perfusion at 37°C. Hearts were rinsed free of blood with a nominally Ca 2+ -free solution containing (in mM): 135 NaCl, 4 KCl, 1.2 MgCl 2 , 1.2 NaH 2 PO 4 , 10 HEPES, 11 glucose, pH 7.4 (NaOH adjusted), and subsequently digested by a solution supplemented with 50 µM Ca 2+ and collagenase type II (1 mg/mL, Worthington, Allschwil, Switzerland) for 15 minutes. Following digestion, the atria were removed and the ventricles transferred to nominally Ca 2+ -free solution, where they were minced into small pieces. Single cardiac myocytes were liberated by gentle trituration of the digested ventricular tissue and filtered through a 100 µm nylon mesh. Ventricular mouse cardiomyocytes were used after an extracellular calcium increase procedure to avoid calcium overload when applying extracellular solutions in electrophysiology assays.
Electrophysiology
Whole-cell currents were measured at room temperature (22-23°C) using a VE-2 amplifier (Alembic Instrument, USA). The internal pipette solution was composed of (in mM) 60 CsCl, 70 Cs-aspartate, 1 MgCl 2 , 10 HEPES, 11 EGTA and 5 Mg-ATP, pH 7.2, with CsOH. The external solution contained (in mM) 130 NMDGCl, 5 CsCl, 2 CaCl 2 , 1.2 MgCl 2 , 10 HEPES and 5 D-glucose, pH 7.4, with CsOH. Data were analysed using pClamp software, version 10.2 (Axon Instruments, Union City, California, USA). Calcium current densities (pA/pF) were calculated dividing the peak current by the cell capacitance. Activation curves and steadystate inactivation curves were fitted with the following single Boltzmann equation: y=1/ (1+exp [(Vh-V 50 )/k]), in which y is the normalized conductance or peak current at a given holding potential (Vh); V 50 is the voltage at which half of the channels are activated (V 50 , act) or inactivated (V 50 , inact) respectively, and k is the slope factor.
Statistical Analysis
Data are represented as means ± S.E.M. Statistical analyses were performed using Prism7 GraphPad™ software. Unless otherwise specified in the figure legends, a Mann-Whitney two-tailed U test was used to compare two groups. p<0.05 was considered significant. N referees to number of mice/hearts used and n to number of isolated cardiomyocytes used.
Results
Dystrophin protein expression is reduced in age-dependently manner in MHC-Cre mouse hearts
As briefly described in the methods section, Dmd flox+ mice have been generated and used as a control for the Cre recombinase activity. Western blots were performed using heart lysates from wild-type (WT) (Dmd flox-/ MHC-Cre figure 1A , dystrophin expression was efficiently suppressed in dystrophin KO compared to WT hearts. Surprisingly, in the non-floxed Dmd gene MHC-Cre + littermates, also used as controls, dystrophin expression was greatly reduced (Fig. 1A , compare lane 2 and 6 with lane 3-5). In contrary, the presence of the floxed element in Dmd gene only did not affect the dystrophin expression (Suppl. Fig. 1A) . To address the question of the time course of this observation, western blots were performed on hearts from 8-, 10-, 12-, and 26-week-old mice. As shown in figure 1B , the decrease of dystrophin protein was more pronounced with age. To confirm that the loss of dystrophin expression was age-dependent, western blots were performed on 8-and 12-week-old mouse hearts from MHC-Cre between control and MHC-Cre + hearts at 8 weeks, at 12 weeks dystrophin expression was significantly decreased by 50 ± 10% in MHC-Cre + hearts compared to the respective controls ( Fig. 2A and 2B) . Finally, immunostainings on cardiac sections of 12-week-old mouse hearts confirmed the decrease of dystrophin expression at the lateral membrane of MHC-Cre + isolated ventricular cardiomyocytes compared to their littermate controls (MHC-Cre -) (Fig. 3A) .
Dmd RNA expression is reduced in MHC-Cre hearts
To investigate at which level Cre affects dystrophin protein expression, we performed quantitative RT-PCR using RNAs extracted from >12-week-old mouse hearts. As shown in figure 3B , the relative increase of ΔCt measured with MHC-Cre + hearts correspond to a ~50% reduction in Dmd mRNA level in MHC-Cre + com- A) Western blots showing dystrophin expression in MHC-Cre -and MHC-Cre + mouse hearts from 8-week-old and 12-week-old mice. B) Quantification of dystrophin expression from western blots shown in A (N=3 for each condition). * p < 0.05, one-way ANOVA followed by Sidak's multiple comparisons test.
pared to the control mice (MHC-Cre -) (Fig. 3B ). This result suggests that Cre decrease mRNA expression by an unknown mechanism.
Calcium current I CaL but not Na v 1.5 expression is altered in MHC-Cre
+ cardiomyocytes Considering the role of dystrophin in the function and regulation of various ion channels, we recorded calcium currents in isolated cardiomyocytes of Cre-expressing cardiomyocytes. Cardiomyocytes from 12-week old MHC-Cre + mice showed a decreased current density in compared to MHC-Cre - (Fig. 4A) . Since dystrophin regulates sodium channel expression in cardiac myocytes, we also studied Na v 1.5 expression in wholeheart lysates with western blots. Interestingly, Na v 1.5 expression did not differ between MHC-Cre + hearts compared to controls, neither in young nor older adult hearts (Fig. 4B) .
The TNT-Cre mouse line may be a better alternative model
To check whether another cardiac-specific Cre-expressing mouse line also shows a reduction in dystrophin expression, western blots were performed using heart lysates from TNT-Cre + mice, a mouse line where Cre recombinase is under the control of the rat troponin T2 cardiac promoter. This strain has been a useful tool for generating early cardiomyocyte-specific mutants as Cre is mainly expressed during embryogenesis 9 . As shown in Fig. 5 , no decrease in dystrophin protein expression was observed in old adult TNT-Cre + mouse hearts compared to control littermates (TNTCre -) (Fig. 5A) . In old adult TNT-Cre + mice, moreover, neither Na v 1.5 expression (Fig. 5B) nor calcium currents (Fig. 5C) were altered in comparison with control heart lysates and cardiomyocytes. Interestingly, Cre expression could not be observed in adult TNTCre hearts. Cre expression was however noticeable in heart lysates from newborn TNT-Cre + mice (Suppl. Fig.  1B ). In addition, when TNT-Cre + mice were crossed with either Snta1-floxed or Dlg1-floxed genes, coding respectively for α1-syntrophin and the MAGUK protein SAP97, both proteins were down regulated. A similar down-regulation was observed in MHC-Cre + mice in which either Snta1 or Dlg1 was floxed. These observations confirm that Cre functions properly in both TNT-Cre and MHC-Cre mouse lines (Suppl. Fig. 2A and 2B ).
Figure 3. Dystrophin expression is altered in adult MHC-Cre
+ mouse hearts at protein and mRNA level. A) Immunostainings showing decreased dystrophin signal (red) at the lateral membrane (white arrows), in cardiomyocytes expressing Cre (green) (N=3 for each condition). B) Decreased mRNA levels for dystrophin (increased ∆CT) are also observed in adult MHC-Cre + mouse hearts compared with control littermates (MHC-Cre -) (N=4 for each condition). ** p < 0.01, t-test two tailed.
Discussion MHC-Cre mice have been extensively used to alter the expression of various cardiac genes [10] [11] [12] . Our present work however strongly suggests that the MHC-Cre model should be carefully characterized before using it for any experiment. This recommendation stems from our following findings. Firstly, Cre expression alone reduces dystrophin protein and mRNA expression from about 12 weeks of age, while dystrophin is a crucial protein in many cardiac processes, and dystrophin reduction has been observed in human diseased cardiomyocytes 4 . Secondly, the L-type calcium current density is decreased by about 40%. Calcium current is piv- 3 . Given that the constitutive expression of Cre in the MHC-Cre model may underlie the aforementioned problems, an αMHC-MerCreMer mouse line has been generated 13 . MerCreMer is a fusion protein 14 . In 2013, two groups moreover showed that the expression of Cre recombinase after induction with tamoxifen is linked to cardiac fibrosis and DNA damage leading to heart failure and death 15, 16 . Recently, raloxifene, another estrogen receptor activator, has been proposed as a replacement for tamoxifen. Raloxifene induces Cre expression in a similar way, and no cardiac dysfunctions have been reported as yet 17 . However, the complexity of the administration procedure of raloxifene limits its utilization. Another proposed strategy is to regulate Cre recombinase expression with a reverse tetracycline transactivator, specifically expressed in the heart 18 . Using this approach, doxycycline added to food and drink inhibits the Cre expression 18 . Once doxycycline is removed, the Cre enzyme is produced. However, to our knowledge, the effect of this approach on cardiac function has not been investigated yet. Recently Werfel et al. established a promising approach for cardiac gene inactivation by transfer of the Cre recombinase gene using adeno-associated viral vectors serotype 9 19 . Such technology may allow the strong inactivation of the floxed gene specifically in cardiac tissue without adverse side effects on cardiac functions 19 . In the present study, we unexpectedly observed that expression of the sodium channel Na v 1.5 is not affected by Cre expression, despite the role of dystrophin in the stabilization of Na v 1.5 at the lateral sarcolemma, which has been demonstrated in dystrophin-deficient mdx 5cv mice 5. One may speculate that, because dystrophin expression is lost at an earlier time point in mdx 5cv than in MHC-Cre + mice, Na v 1.5
is not yet affected in MHC-Cre + mice. In addition, an increase in utrophin expression may compensate for the dystrophin down-regulation, which has already been reported in previous studies [20] [21] [22] . Importantly, in a recent study, the presence of more than 600 loxP like sites in the genome of C57Bl/6 mice has been reported 3 . Based on this observation, one may propose that many genes of the MHC-Cre + mouse strain can be modified, leading to various unexpected effects. As of yet, no comprehensive proteomic analysis has been performed on MHC-Cre + model, we may speculate that other genes and proteins are dysregulated in this model, which could compensate for the down-expression of Na v 1.5 channels. Surprisingly, the expression of Cre recombinase under the rat troponin T2 cardiac promoter affected neither dystrophin expression nor the calcium current. However, a critical limitation for the interpretation of this finding is that the MHC-Cre + and TNT-Cre + mice differed in their mixed genetic background levels. As already reported, the background of the mice is important for the onset of cardiac dysfunctions due to Cre recombinase expression 23 . Mice on mixed backgrounds seem to be more resistant to developing cardiac dysfunction in response to Cre expression 23 . Consequently, it is important to repeat these experiments with MHC-Cre + and TNT-Cre + mice with mice on a pure background.
In conclusion, the findings of the present study are a clear warning to all researchers who use engineered mouse lines, especially MHC-Cre. We strongly recommend keeping our results in mind when designing experimental procedures involving MHC-Cre mice, and probably other Cre-expressing mouse models. Experimenters should carefully choose the proper controls, and consider the age, and likely the sex of the animals.
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